Argentum Succeeds In Starting Patent Cancellation Trial Against Janssen's ZYTIGA

Published: Sep 19, 2016

NEW YORK, Sept. 19, 2016 /PRNewswire/ -- Today, the U.S. Patent & Trademark Office (PTO) granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the sole unexpired patent listed as covering Janssen Oncology, Inc.'s ZYTIGA® (abiraterone acetate) drug in the Food & Drug Administration's Orange Book that will remain after Janssen's initial patent on the drug expires later this year.  Argentum challenges claims 120 of Janssen's U.S. Patent No. 8,822,438, which the Orange Book states will expire in 2027. 

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers.

The PTO concluded that Argentum has established a "reasonable likelihood that it will prevail with respect to its challenge to claims 120 of the '438 patent on the asserted grounds."  The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board.  A final decision on patentability in the IPR is due within 1 year.

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.

Logo -  

To view the original version on PR Newswire, visit:

SOURCE Argentum Pharmaceuticals

Back to news